Close Menu


Title: Methods of Modulating Lipid Concentrations in Eukaryotic Cells
Patent Number: 8,435,790
Filed: July 24, 2009
Lead Inventor: Robert Farese, University of California, Oakland

Title: miR-182-, miR-191-, miR-199a-based Methods for the Diagnosis and Prognosis of Acute Myeloid Leukemia
Patent Number: 8,431,342
Filed: Oct. 7, 2011

Title: iRNA Agents with Biocleavable Tethers
Patent Number: 8,426,377
Filed: March 15, 2010
Lead Inventor: Muthiah Manoharan, Alnylam Pharmaceuticals

NEW YORK (GenomeWeb News) – Genetic Technologies today said that the US Patent and Trademark Office has granted a request from a company being sued by GTG for a second ex parte re-examination of a patent.

Veritas Bio, a biotechnology holding company established by two co-founders of expressed RNAi firm Nucleonics, said this week that the US Patent and Trademark Office has issued a notice of allowance on a patent application covering a novel liver-directed RNAi delivery technology.

Title: RNA Sequence-Specific Mediators of RNA Interference
Patent Number: 8,420,391
Filed: Oct. 4, 2010
Lead Inventor: Thomas Tuschl, Max Planck Institute

Santaris Pharma announced this week that the US Patent and Trademark Office has issued a inter partes re-examination certificate for a US patent held by the company and covering locked nucleic acids.

Title: Expression System
Patent Number: 8,415,148
Filed: Aug. 2, 2011
Inventor: Jacques Perrault, San Diego State University

Title: Inhibition of Versican with siRNA and Other Molecules
Patent Number: 8,410,067
Filed: Oct. 31, 2008
Lead Inventor: Thomas Wight, Benaroya Research Institute

Title: microRNA as a Cancer Progression Indicator and Its Use for Treating Cancer
Patent Number: 8,404,437
Filed: March 29, 2011


The US Patent and Trademark Office is opening another interference proceeding in the CRISPR patent fight.

There's increasing genetic evidence that a number of ancient hominins may have contributed to the human gene pool, according to Discover's The Crux blog.

The Japan News writes that Japan needs to seize the opportunity to ensure that a wide number of people benefit from personalized cancer treatments.

In Cell this week: messenger RNA expression and translation, RNA localization atlas, and more.